Sionna Therapeutics, Inc. (NASDAQ:SION) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Sionna Therapeutics, Inc. (NASDAQ:SION) has earned an average rating of “Moderate Buy” from the thirteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and three have issued a strong buy rating on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $53.2222.

A number of brokerages recently commented on SION. Weiss Ratings restated a “sell (d-)” rating on shares of Sionna Therapeutics in a report on Friday, May 8th. Citizens Jmp restated a “market outperform” rating and set a $63.00 target price on shares of Sionna Therapeutics in a report on Tuesday, May 26th. Freedom Capital cut Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 20th. Guggenheim raised their target price on Sionna Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Finally, BTIG Research reaffirmed a “buy” rating and issued a $58.00 price target on shares of Sionna Therapeutics in a research report on Wednesday, May 13th.

Insider Transactions at Sionna Therapeutics

In other Sionna Therapeutics news, Director Peter A. Thompson sold 184,639 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $46.22, for a total value of $8,534,014.58. Following the sale, the director owned 2,671,822 shares of the company’s stock, valued at $123,491,612.84. This trade represents a 6.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 184,639 shares of the stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $46.22, for a total value of $8,534,014.58. Following the completion of the sale, the director directly owned 2,671,822 shares in the company, valued at $123,491,612.84. This represents a 6.46% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,717,962 shares of company stock worth $77,571,889 in the last ninety days. 5.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Sionna Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. TD Asset Management Inc raised its position in shares of Sionna Therapeutics by 74.3% during the 3rd quarter. TD Asset Management Inc now owns 87,082 shares of the company’s stock worth $2,561,000 after acquiring an additional 37,116 shares in the last quarter. UBS Group AG raised its position in shares of Sionna Therapeutics by 91.1% during the 4th quarter. UBS Group AG now owns 89,177 shares of the company’s stock worth $3,669,000 after acquiring an additional 42,511 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Sionna Therapeutics by 3.7% during the 4th quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock worth $48,749,000 after acquiring an additional 41,797 shares in the last quarter. Jennison Associates LLC raised its position in shares of Sionna Therapeutics by 11.8% during the 4th quarter. Jennison Associates LLC now owns 1,115,278 shares of the company’s stock worth $45,883,000 after acquiring an additional 117,903 shares in the last quarter. Finally, Eventide Asset Management LLC acquired a new stake in shares of Sionna Therapeutics during the 4th quarter worth about $26,290,000.

Sionna Therapeutics Trading Up 1.9%

NASDAQ SION opened at $42.97 on Tuesday. The stock has a market cap of $1.94 billion, a PE ratio of -22.26 and a beta of 1.30. Sionna Therapeutics has a twelve month low of $15.10 and a twelve month high of $48.44. The stock has a fifty day simple moving average of $39.80 and a 200-day simple moving average of $39.47.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). Research analysts predict that Sionna Therapeutics will post -2.57 EPS for the current year.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.